

SECRETARY OF THE SEN

04 FEB 13 PM 4:11

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Aventis Pharmaceuticals (formerly known as Aventis Pharmaceuticals Inc.)			
2. Address <input type="checkbox"/> Check if different than previously reported 801 Pennsylvania Avenue, NW - Suite 725			
3. Principal Place of Business (if different from line 2) Washington, DC 20004 City: State/zip (or Country)			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
Ann Taylor	(202) 898-3183	ann.taylor@aventis.com	56838-12
7. Client Name <input type="checkbox"/> Self			6. House ID #
			35186000

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December)
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇨ Termination Date _____11. No Lobbying **INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇨ \$ _____ <div style="text-align: center;">Income (nearest \$20,000)</div>	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇨ \$ <u>127,071,200.00</u> <div style="text-align: center;">Expenses (nearest \$20,000)</div>
14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
<input type="checkbox"/> Method A. Reporting amounts using LDA definition.	
<input type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code	
<input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code	

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

LD-2 (REV. 4/03)

PAGE 1 of -

000004
200

Registrant Name uticals (formerly known as Aventis Pha Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R.1 "Medicare Drug Benefit and Modernization Act of 2003"
S.1 "Medicare Drug Benefit and Modernization Act of 2003"
H.R.1 "Medicare Prescription Drug, Improvement and Modernization Act of 2003"
H.R.1 "Medicare Prescription Drug, Improvement and Modernization Act of 2003 Conference Agreement"

All provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Eddie Evans	
Ann Taylor	
Richard Hodge	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceutical part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that essential pharmaceutical benefit coverage available to the Medicare population.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Form LD-2 (Rec. 4/03)

Page 2 c

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide the information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Discussions with the Centers for Medicaid and Medicare Services (CMS) on reimbursement policy in Medicare Part B.

17. House(s) of Congress and Federal agencies contacted Check if None

Centers for Medicaid and Medicare Services, Department of Health and Human Services.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Eddie Evans	
Ann Taylor	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceu part of Aventis SA. Aventis Pharmaceuticals interest in this issue is to ensure that essential pharmaceutical benefit coverage available to the Medicare population.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Form LD-2 (Rev. 4/03)

Page 3 c

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

S.1225 "Greater Access to Affordable Pharmaceutical Act"
All provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Eddie Evans	
Judy Cook	
Ann Taylor	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is a part of Aventis SA. Aventis Pharmaceuticals interest in this issue is to ensure that the legislation supports continued development of new and better patients.

Signature _____ Date _____

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code. Provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Switch of prescription drugs to over-the-counter.

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Eddie Evans	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is a part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that public policy supports continued development of new and better pharmaceuticals that are needed by patients.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy & Pharmaceutical Programs

Form LD-2 (Rec. 4/03)

Page 5 c

Printed Name and Title Ann Taylor, Director, Health Policy & Pharmaceutical Programs

Form LD-2 (Rev. 4/03)

Page 6 of 0

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code. Provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

H.R. 2673 "Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2004"
S.1427 "Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2004"
All provisions relating to reimportation.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Eddie Evans	
Judy Cook	
Ann Taylor	
Richard Hodge	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under french Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is a part of Aventis SA. Aventis Pharmaceuticals is interested in this bill to ensure that the safety of U.S. pharmaceuticals are protected for all Americans.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Form LD-2 (Rec. 4/03)

Page 7 c

000000471206

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 2427 "Pharmaceutical Market Access Act of 2003"
All Provisions.

17. House(s) of Congress and Federal agencies contacted Check if None


U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Richard Hodge	
Ann Taylor	
Eddie Evans	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that the U.S. pharmaceutical industry is not subject to unfair price restraints and that the American public is not subjected to unsafe pharmaceuticals.

Signature  Date 2/13/04

